世界の前臨床画像市場の規模は売上ベースで、2024年に9億4,600万ドルと推定され、2024年から2029年にかけて5.9%のCAGRで成長し、2029年には12億5,900万ドルに達すると予測されます。この包括的な調査には、業界動向の徹底的な調査、綿密な価格分析、特許の精査、会議やウェビナーから得られた洞察、主要な利害関係者の特定、および市場の購買ダイナミクスの微妙な理解が含まれます。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.1.1 Key data from primary sources
2.2.2.1.2 Key industry insights
2.2.2.1.3 Breakdown of primaries
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.7.1 METHEDOLOGY RELATED LIMITATIONS
2.7.2 SCOPE RELATED LIMITATIONS
2.8 IMPACT OF RECESSION ON PRECLINICAL IMAGING MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.2 MARKET RESTRAINTS
5.2.3 MARKET OPPORTUNITIES
5.2.4 MARKET CHALLENGES
5.3 KEY INDUSTRY TRENDS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 PHOTOACOUSTIC TOMOGRAPHY - MRI TECHNOLOGY
5.4.1.2 MULTISPECTRAL OPTOACOUSTIC TOMOGRAPHY (MSOT)
5.4.1.3 FUNCTIONAL ULTRASOUND (FUS) NEUROIMAGING
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.3 ADJACENT TECHNOLOGY
5.5 ECOSYSTEM ANALYSIS
5.6 VALUE/ SUPPLY CHAIN ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR PRECLINICAL IMAGING
5.8.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES
5.8.3 MAJOR PATENTS
5.8.4 PATENT FILED
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.9.2 REGULATORY ANALYSIS
5.9.2.1 NORTH AMERICA
5.9.2.2 EUROPE
5.9.2.3 ASIA PACIFIC
5.9.2.4 LATIN AMERICA
5.9.2.5 MIDDLE EAST AND AFRICA
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE TREND, BY REGION
5.10.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.11 KEY CONFERENCES & EVENTS IN 2024-2025
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 CASE STUDIES
5.14 UNMET NEEDS
5.14.1 END-USER EXPECTATIONS
5.15 BUSINESS MODEL ANALYSIS
5.16 REIMBURSEMENT SCENARIO ANALYSIS
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.18 TRADE ANALYSIS
Note: Investment & Funding Scenario is not available for this market.
6 PRECLINICAL IMAGING MARKET, BY PRODUCT TYPE(USD MILLION; 2018-2029)
6.1 INTRODUCTION
6.2 IMAGING SYSTEMS
6.2.1 OPTICAL IMAGING SYSTEMS
6.2.1.1 BIOLUMINESCENCE IMAGING SYSTEMS
6.2.1.2 FLUORESCENCE IMAGING SYSTEMS
6.2.1.3 OTHER OPTICAL IMAGING SYSTEMS
6.2.2 NUCLEAR IMAGING SYSTEMS
6.2.2.1 MICRO-PET IMAGING SYSTEMS
6.2.2.1.1 STANDALONE PET IMAGING SYSTEMS
6.2.2.1.2 PET/CT IMAGING SYSTEMS
6.2.2.1.3 PET/ MRI IMAGING SYSTEMS
6.2.2.2 MICRO-SPECT IMAGING SYSTEMS
6.2.2.2.1 STANDALONE SPET IMAGING SYSTEMS
6.2.2.2.2 SPET/CT IMAGING SYSTEMS
6.2.2.2.3 SPET/ MRI IMAGING SYSTEMS
6.2.2.3 TRIMODALITY (SPECT/PET/CT) IMAGING SYSTEMS
6.2.3 MICRO-MRI SYSTEMS
6.2.4 MICRO-ULTRASOUND SYSTEMS
6.2.5 MICRO-CT SYSTEMS
6.2.6 PHOTOACOUSTIC IMAGING SYSTEMS
6.2.7 MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS
6.3 REAGENTS
6.3.1 PRECLINICAL OPTICAL IMAGING REAGENTS
6.3.1.1 PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS
6.3.1.1.1 LUCIFERINS
6.3.1.1.2 COELENTERAZNE
6.3.1.1.3 FURIMAZINE
6.3.1.2 PRECLINICAL FLUORESCNT IMAGING REAGENTS
6.3.1.2.1 GREEN FLUORESCENT PROTEINS
6.3.1.2.2 RED FLUORESCENT PROTEINS
6.3.1.2.3 INFRARED DYES
6.3.2 PRECLINICAL NUCLEAR IMAGING REAGENTS
6.3.2.1 PRECLINICAL PET TRACERS
6.3.2.1.1 FLUORINE-18-BASED PRECLINICAL PET TRACERS
6.3.2.1.2 CARBON-11-BASED PRECLINICAL PET TRACERS
6.3.2.1.3 COPPER-64-BASED PRECLINICAL PET TRACERS
6.3.2.1.4 OTHER PET TRACERS
6.3.2.2 PRECLINICAL SPECT PROBES
6.3.2.2.1 TECHNETIUM-99M-BASED PRECLINICAL SPECT PROBES
6.3.2.2.2 IODINE-131-BASED PRECLINICAL SPECT PROBES
6.3.2.2.3 GALLIUM-67-BASED PRECLINICAL SPECT PROBES
6.3.2.2.4 THALLIUM-201-BASED PRECLINICAL SPECT PROBES
6.3.2.2.5 OTHER SPECT PROBES
6.3.3 PRECLINICAL MRI CONTRAST AGENTS
6.3.3.1 GADOLINIUM-BASED PRECLINICAL CONTRAST AGENTS
6.3.3.2 IRON-BASED PRECLINICAL CONTRAST AGENTS
6.3.3.3 MANGANESE-BASED PRECLINICAL CONTRAST AGENTS
6.3.4 PRECLINICAL ULTRASOUND CONTRAST AGENTS
6.3.5 PRECLINICAL CT CONTRAST AGENTS
6.3.5.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
6.3.5.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
6.3.5.3 GOLD NANOPARTICLES
6.3.5.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS
6.4 SOFTWARE
7 PRECLINICAL IMAGING MARKET, BY APPLICATION TYPE(USD MILLION; 2018-2029)
7.1 INTRODUCTION
7.2 ONCOLOGY
7.3 CARDIOLOGY
7.4 NEUROLOGY
7.5 INFECTIOUS DISEASES
7.6 IMMUNOLOGY & INFLAMMATION
7.7 OTHER APPLICATIONS
8 PRECLINICAL IMAGING MARKET, BY END USER(USD MILLION; 2018-2029)
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3 ACADEMIC & RESEARCH CENTERS
8.4 IMAGING CENTERS
8.5 OTHER END USERS
9 PRECLINICAL IMAGING MARKET, BY REGION(USD MILLION; 2018-2029)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.2.3 NORTH AMERICA: IMPACT OF ECONOMIC RECESSION
9.3 EUROPE
9.3.1 UK
9.3.2 GERMANY
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.3.7 EUROPE: IMPACT OF ECONOMIC RECESSION
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 REST OF ASIA PACIFIC
9.4.5 ASIA PACIFIC: IMPACT OF ECONOMIC RECESSION
9.5 LATAM
9.5.1 LATIN AMERICA: IMPACT OF ECONOMIC RECESSION
9.5.2 BRAZIL
9.5.3 MEXICO
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST AND AFRICA
9.6.1 GCC COUNTRIES
9.6.2 REST OF MIDDLE EAST AND AFRICA
9.6.3 MIDDLE EAST & AFRICA: IMPACT OF ECONOMIC RECESSION
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS (2023)
10.4 MARKET SHARE ANALYSIS (2023)
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.5.5.1 COMPANY FOOTPRINT
10.5.5.2 REGION FOOTPRINT
10.5.5.3 PRODUCT & SERVICE FOOTPRINT
10.5.5.4 TYPE FOOTPRINT
10.5.5.5 END USER FOOTPRINT
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMAPNIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/ SMES, 2023
10.6.5.1 DETAILED LIST OF KEY STARTUPS/SMES
10.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
10.7 VALUATION AND FINANCIAL METRICS OF PRECLINICAL IMAGING VENDORS
10.8 BRAND COMPARATIVE ANALYSIS
10.9 COMPETITIVE SCENARIO AND TRENDS
10.9.1 PRECLINICAL IMAGING MARKET: PRODUCT LAUNCHES
10.9.2 PRECLINICAL IMAGING MARKET: DEALS
10.9.3 PRECLINICAL IMAGING MARKET: OTHER DEVELOPMENTS
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 KEY PLAYERS
11.1.1 BRUKER CORPORATION
11.1.2 REVVITY, INC.
11.1.3 MR SOLUTIONS
11.1.4 MEDISO LTD.
11.1.5 TRIFOIL IMAGING
11.1.6 FUJIFILM VISUAL SONICS
11.1.7 MILABS B.V.
11.1.8 ASPECT IMAGING LTD.
11.1.9 LI-COR BIOSCIENCES
11.1.10 ICONEUS
11.1.11 ADVANCED MOLECULAR VISION
11.1.12 IVIM TECHNOLOGY CORP
11.1.13 CUBRESA, INC.
11.1.14 BERTHOLD TECHNOLOGIES GMBH & CO.KG
11.1.15 SOFIE
11.1.16 VIEWWORKS
11.1.17 AI4R
11.1.18 KUB TECHNOLOGIES
11.1.19 MEDIKORS
11.1.20 MILTENYI BIOTEC & OTHERS
12 APPENDIX
12.1 INSIGHTS OF INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 CUSTOMIZATION OPTIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
